Health Care · Pharmaceutical Preparations

EWTX Edgewise Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 171007284 filings
Russell 2000

EWTX at a glance

Edgewise Therapeutics, Inc. (EWTX, SEC CIK 1710072) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Edgewise Therapeutics, Inc. (EWTX) shares worth $1.0 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Donovan Joanne M. on November 16, 2026 of 854 shares at $45.48 per share.
  • In the last 90 days, EWTX insiders reported 0 open-market purchases ($0) and 2 open-market sales ($241K) on Form 4, a net sale of $241K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 2 sells
Net −$241K
13F holders
28 funds
$1.0B · +0 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Discovery and development of precision small molecule therapies targeting severe skeletal and cardiac muscle diseases
  • New emphasis on sevasemten, an oral fast myosin inhibitor in late-stage trials for Duchenne and Becker muscular dystrophies with recent FDA Fast Track and Orphan Drug designations
  • Strategic focus shift to advancing muscle fiber stabilizing therapies with potential use as standalone or combination treatment, expanding clinical-stage muscular dystrophy and cardiac programs including EDG-7500 and EDG-15400
  • Pipeline growth with multiple clinical-stage assets and new preclinical candidates, including EDG-003 targeting cardiometabolic diseases
  • FDA approvals and setbacks in gene and exon skipping therapies for Duchenne highlight continued unmet need; Edgewise promotes mutation-agnostic, mechanistically novel approach potentially addressing broader patient populations

Risk Factors

  • FDA and EMA regulatory approval risks; lengthy, unpredictable processes may delay product commercialization
  • Macroeconomic risk from U.S. banking sector disruptions; Silicon Valley Bank failure may limit capital market access
  • Dependence on third-party manufacturers for sevasemten, EDG-7500, EDG-15400; supply disruptions could delay trials or commercialization
  • Competition risk from faster, safer, or cheaper products by unnamed competitors could reduce market opportunities
  • Financial risk: net loss $167.8M in 2025, accumulated deficit $546.4M; need for additional capital may dilute stockholders or restrict operations

Management Discussion & Analysis

  • Net loss $167.8M in 2025 vs $133.8M in 2024, operating expenses rose $32.6M to $191.4M driven by R&D and G&A increases
  • R&D expenses $151.4M vs $127.0M (+19%), led by sevasemten $52.5M, EDG-7500 $18.4M, and new EDG-15400 $7.6M clinical program costs
  • General & admin expenses $40.0M vs $31.9M (+25.6%) due to higher personnel and professional fees
  • Cash from financing $196.1M in 2025 including $200M direct offering; cash used in operating activities $143.8M; cash and equivalents $530.1M at year-end
  • Management expects increasing expenses from advancing clinical trials, regulatory activities, and commercial preparation; risks include clinical trial outcomes, regulatory timing, capital needs, and macroeconomic uncertainties

AI summary of the EWTX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added tax risk: Sevasemten Sale may create material cash tax obligations despite approximately $319.7 million federal NOL carryforwards
  • Most materially updated regulatory risk: FDA reorganization and workforce reductions could delay reviews, inspections and clinical development timelines
  • Competitive risk: Cytokinetics received Myqorzo approvals in the US, Europe and certain Asian countries during late 2025 and early 2026
  • Financial risk: $1,743.9 million in cash, equivalents and marketable securities expected to fund operations for at least 12 months
  • Legal compliance risk: GDPR violations can trigger fines up to €20,000,000 or 4% of worldwide annual turnover

Management Discussion & Analysis

  • No product revenue; net income $1,166.2M vs $40.7M loss YoY, driven by $1,348.1M Sevasemten-sale gain
  • Operating margin not meaningful: operating loss $46.1M vs $46.9M YoY, while effective tax rate was 11.8%
  • Best program: EDG-7500 R&D $6.8M vs $4.5M; worst: Sevasemten $2.5M vs $13.6M
  • Cash, equivalents and securities $1,743.9M vs $530.1M at December 31, 2025; operating cash outflow $163.3M
  • Phase 3 EDG-7500 trial planned for Q4 2026; GRAND CANYON study missed endpoints, threatening milestone payments

AI summary of the EWTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026 announced
  • Full earnings details, including financial metrics and management commentary, in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Cash, equivalents and marketable securities $1,743.9M, substantially strengthening funding for cardiovascular development
  • Sevasemten sale generated $1.348B gain and $1.396B upfront cash, driving $1,166.2M net income versus $40.7M loss
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 2026 net loss $57.3M, or $0.53 per share, versus $36.1M, or $0.34, in Q2 2025
  • Cash, equivalents and marketable securities $460.7M at June 30; pro forma $2.01B after $1.55B Servier upfront proceeds

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Press release attached as Exhibit 99.1, containing the substantive results and management commentary
Filed Jul 16, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Servier transaction produced $1.55B upfront cash and up to $1.1B milestones, transforming Edgewise into a cardiovascular-focused company
  • Pro forma cash and equivalents rose to $1.532B, with total assets reaching $2.014B and stockholders’ equity $1.755B

AI summaries of EWTX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for EWTX

Don't miss the next EWTX filing

  • Alerts as it files. A push when EWTX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut EWTX, by share count.
  • Ask anything. An AI agent that reads every EWTX filing and answers with sources.

EWTX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Donovan Joanne M.SellNov 16, 2026$45.48
Nofi MichaelMNov 10, 2026-
Nofi MichaelSellNov 10, 2026$45.43
Nofi MichaelMNov 10, 2026-
Fox Jonathan CAOct 1, 2026-
Donovan Joanne M.SellAug 13, 2026$43.41
Derakhshan BehradMAug 12, 2026-
Derakhshan BehradMAug 12, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$114.4M-$158.8M-$191.4M
Net Income-$100.2M-$133.8M-$167.8M
Balance Sheet
Total Assets$340.0M$486.8M$552.6M
Equity$318.8M$459.2M$522.3M
ROE-31.4%-29.1%-32.1%
Per Share
EPS-$-1.45$-1.63
Cash Flow
Operating CF-$91.9M-$109.0M-$143.8M
CapEx$5.7M$1.3M$256K

Source: XBRL data in Edgewise Therapeutics, Inc. (EWTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate EWTX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
EWTX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$1.03B
Q2 202628$1.11B
Q1 202628$672.5M
Q4 202524$563.3M
Q3 202523$311.7M
Q2 202522$265.7M
Q1 202522$241.2M
Q4 202418$312.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 193 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

EWTX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 10, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Oct 2, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 14, 2026--
4Aug 14, 2026--
4Aug 14, 2026--
4Aug 14, 2026--
4Aug 14, 2026--
4Aug 14, 2026--
10-QAug 6, 2026Analysis
SC 13GAug 6, 2026-
8-KAug 6, 2026Analysis-
4Jul 17, 2026--
8-KJul 16, 2026Analysis-
8-KJul 13, 2026Analysis-
4Jul 2, 2026--
4Jul 1, 2026--
4Jun 17, 2026--

Related Health Care companies

All Health Care →

EWTX SEC filings: frequently asked questions

Are EWTX insiders buying or selling?

In the last 90 days, Edgewise Therapeutics, Inc. (EWTX) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $240,627 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold EWTX stock?

As of September 30, 2026, the largest Edgewise Therapeutics, Inc. (EWTX) holders among the 13F filers tracked by SignalX were BlackRock ($295.3 million), Vanguard Capital Management LLC ($159.6 million), Bank of America Corp ($105.3 million), Citadel Advisors LLC ($104.4 million), State Street Corp ($77.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the main risks in EWTX's latest 10-K?

In the 10-K filed February 26, 2026, Edgewise Therapeutics, Inc. (EWTX) flagged: FDA and EMA regulatory approval risks; lengthy, unpredictable processes may delay product commercialization. Macroeconomic risk from U.S. banking sector disruptions; Silicon Valley Bank failure may limit capital market access. (AI summary of the Risk Factors section.)

What did EWTX report in its latest 8-K?

Edgewise Therapeutics, Inc. (EWTX) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026 announced.

What are the latest EWTX SEC filings?

Edgewise Therapeutics, Inc. (EWTX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 18, 2026.

What is EWTX's SEC CIK number?

Edgewise Therapeutics, Inc. (EWTX)'s SEC Central Index Key (CIK) is 1710072. EDGAR lists every EWTX filing under that number.

Ask anything about EWTX

The research agent reads EWTX's filings, financials, insider trades and 13F holders, then answers with sources.